Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 7 | Journal for ImmunoTherapy of Cancer

Figure 7

From: Optimizing immune-related tumor response assessment: does reducing the number of lesions impact response assessment in melanoma patients treated with ipilimumab?

Figure 7

Bland-Altman plots demonstrate the interobserver variability of measurements by irRC simulating RECIST1.0 (A), and by irRC simulating RECIST1.1 (B), on baseline scans in randomly selected 30 patients. The 95% limits of agreement of measurements by irRC simulating RECIST1.0 were (-23.0%, 14.1%; Figure 7A, dashed lines), while the 95% limits of agreement of measurements by irRC simulating RECIST1.1 were (-21.8%, 16.1%; Figure 7B, dashed lines). The dotted lines represent the mean relative difference (%).

Back to article page